MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Devices Conference
02 Febrero 2006 - 6:00AM
Business Wire
MGI PHARMA, INC. (Nasdaq:MOGN) today announced that it will present
at the Merrill Lynch Global Pharmaceutical, Biotechnology and
Medical Devices Conference on Thursday, February 9, 2006 at 10:20
a.m. Eastern Time. Lonnie Moulder, President and Chief Executive
Officer of MGI PHARMA, will give the presentation, which will be
webcast live over the Internet. The conference will be held at the
Grand Hyatt Hotel in New York City. -0- *T What: MGI PHARMA's
presentation at the Merrill Lynch Global Pharmaceutical,
Biotechnology and Medical Devices Conference When: Thursday,
February 9, 2006 at 10:20 a.m. Eastern Time How: Live over the
Internet - simply log on to www.mgipharma.com. In addition to the
live webcast, the presentation will be archived on the Company's
Web site for one week. *T About MGI PHARMA MGI PHARMA, INC. is an
oncology- and acute care-focused biopharmaceutical company that
acquires, researches, develops and commercializes proprietary
products that address the unmet needs of patients. MGI PHARMA
markets Aloxi(R) (palonosetron hydrochloride) injection and
Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the
United States. The Company directly markets its products in the
U.S. and collaborates with partners to reach international markets.
For more information about MGI PHARMA, please visit
www.mgipharma.com. This news release contains certain
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are
typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar
expressions. These forward-looking statements are not guarantees of
MGI PHARMA's future performance and involve a number of risks and
uncertainties that may cause actual results to differ materially
from the results discussed in these statements. Factors that might
cause either company's results to differ materially from those
expressed or implied by such forward-looking statements include,
but are not limited to, the ability of MGI PHARMA's product
candidates to be proven safe and effective in humans, to receive
marketing authorization from regulatory authorities, and to
ultimately compete successfully with other therapies; continued
sales of MGI PHARMA's marketed products; development or acquisition
of additional products; reliance on contract manufacturing; changes
in strategic alliances; continued access to capital; ability of MGI
PHARMA to successfully complete the integration of Guilford with
its existing operations; the risk that the perceived advantages of
the Guilford transaction may not be achieved; and other risks and
uncertainties detailed from time to time in MGI PHARMA's filings
with the Securities and Exchange Commission including its most
recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no duty to
update any of these forward-looking statements to conform them to
actual results.
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Mgi Pharma (MM) (NASDAQ:MOGN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Mgi Pharma (MM) (NASDAQ): 0 recent articles
Más de MGI PHARMA Artículos de Noticias